Oncology A look back to ASCO 2025: Industry comments from iOnctura an... ASCO 2025 may be over, but the insights for the future of oncology are only just beginning.
News NICE backs Roche's non-Hodgkin lymphoma drug Columvi NICE backs NHS use of Roche's Columvi as a second-line therapy for a form of non-Hodgkin lymphoma affecting thousands of people in the UK each year.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
